CloneID: 3G8
Heavy Chain modification: Fc Silent™
Antigen Long Description: 3G8 was prepared by immunizing mice with human PMN (polymorphonuclear leukocytes) cells.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q9ULV2
Specificity Statement: 3G8 binds to CD16 at an epitope which is not the IgG-binding site. This antibody cannot distinguish between CD16a transmembrane isoform found on the surface of NK cells and macrophages (which can trigger the cytolytic response), and the GPI-linked CD16b isoform present on neutrophils or soluble CD16 found in the plasma. CD16 is the low affinity IgG receptor III and binds to aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis and ADCC (antibody-dependent cell-mediated cytotoxicity).
Application Notes (Clone): 3G8 antibody was used to construct a recombinant bispecific scFv (bsscFv) along with the mAb clone F3.3 anti-HLA class II antibody (connected by a (Gly4Ser)4 linker)which was expressed in SF21 insect cells. This bsscFv allows NK cells to target malignant B lymphoid cells and mediates effector cell lysis (ASCC) of the malignant cells (also lysis of primary leukaemia samples). 3G8 is also able to block neutrophil phagocytosis and stimulates NK cell proliferation, and can be used in FC, SPR, IP and IHC studies.